The Claim
One year after discontinuing daily liraglutide 3.0 mg, obese adults experienced an average weight regain of 9.6 kg, with no sustained reduction in body weight or fat mass compared to placebo, indicating that pharmacotherapy with liraglutide does not produce lasting weight maintenance after treatment cessation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
After stopping daily liraglutide 3.0 mg, obese adults regained an average of 9.6 kg within one year, and their body weight and fat mass returned to levels similar to those who took a placebo, showing no long-term weight maintenance from the drug alone.
See the scientific wording
One year after discontinuing liraglutide 3.0 mg daily, obese adults regained an average of 9.6 kg, with no sustained benefit in body weight or fat mass compared to placebo, indicating that pharmacotherapy alone does not produce lasting weight maintenance after treatment ends.
When the drug stops working, the brain no longer receives signals to feel full, so hunger increases and eating goes up. At the same time, the body burns fewer calories because it slows down metabolism after weight loss. Without exercise or other behavior changes to counter this, the extra calories turn into fat, and weight comes back.
What the research says
1 studyWhen people stopped taking the weight-loss drug liraglutide, they gained back about 9.6 kg on average — almost all the weight they lost. The study shows the drug’s effect disappears after stopping, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.